Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7.

[1]  J. Hecht,et al.  A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  P. Fisher,et al.  mda-7 (IL-24): signaling and functional roles. , 2002, BioTechniques.

[3]  J. Roth,et al.  Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo , 2002, Oncogene.

[4]  B. Karlan,et al.  Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500 , 2002, Cancer Gene Therapy.

[5]  B. Karlan,et al.  A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer , 2002, Cancer Gene Therapy.

[6]  M. Retter,et al.  The Protein Product of the Tumor Suppressor Gene, Melanoma Differentiation-Associated Gene 7, Exhibits Immunostimulatory Activity and Is Designated IL-241 , 2002, The Journal of Immunology.

[7]  Minetta C. Liu,et al.  P53 gene mutations: case study of a clinical marker for solid tumors. , 2002, Seminars in oncology.

[8]  B. Dörken,et al.  Adenovirus-mediated overexpression of p14ARF induces p53 and Bax-independent apoptosis , 2002, Oncogene.

[9]  J. Douglas,et al.  Targeted adenoviral vectors , 2002 .

[10]  S. H. van der Burg,et al.  Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  F. McCormick,et al.  Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. , 2002, Cancer cell.

[12]  Stephen G Swisher,et al.  Adenoviral transfer of the melanoma differentiation-associated gene 7 (mda7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR). , 2002, Cancer research.

[13]  M. Gore,et al.  Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Seth,et al.  Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma , 2002, Cancer Gene Therapy.

[15]  L. Broemeling,et al.  Loss of MDA-7 expression with progression of melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Schuler,et al.  Successful Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients With Bladder Cancer by Intravesical Vector Instillation , 2002 .

[17]  P. Fisher,et al.  The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells , 2002, Oncogene.

[18]  D. Curiel,et al.  Conditional gene targeting for cancer gene therapy. , 2001, Advanced drug delivery reviews.

[19]  D. Sze,et al.  Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial , 2001, Gene Therapy.

[20]  S. Pestka,et al.  Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties , 2001, Oncogene.

[21]  A. Sahin,et al.  Down‐regulated melanoma differentiation associated gene (mda‐7) expression in human melanomas , 2001, International journal of cancer.

[22]  Z. Su,et al.  A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Uematsu,et al.  p14ARF Modulates the Cytolytic Effect of ONYX-015 in Mesothelioma Cells with Wild-type p53 , 2001 .

[24]  D. Curiel,et al.  Gene therapy for the treatment of cancer. , 2001, Cancer biotherapy & radiopharmaceuticals.

[25]  R. Vile,et al.  Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. , 2001, Critical reviews in oncology/hematology.

[26]  J. Wolf,et al.  In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  J. Nemunaitis,et al.  Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity , 2001, Gene Therapy.

[28]  J. Roth,et al.  Melanoma Differentiation Associated Gene-7 (mda-7): A Novel Anti-Tumor Gene for Cancer Gene Therapy , 2001, Molecular medicine.

[29]  A. Schatzlein,et al.  Non-viral vectors in cancer gene therapy: principles and progress , 2001, Anti-cancer drugs.

[30]  R. Herrmann,et al.  Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Balmain,et al.  Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis , 2001, Gene Therapy.

[32]  M. Kelly,et al.  E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. , 2001, Human gene therapy.

[33]  A. Venook,et al.  Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial , 2001, Gene Therapy.

[34]  S. Pestka,et al.  Identification of the Functional Interleukin-22 (IL-22) Receptor Complex , 2001, The Journal of Biological Chemistry.

[35]  F. Khuri,et al.  Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Roth,et al.  Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro , 2000, Gene Therapy.

[37]  P. Sweeney,et al.  Ad5CMVp53 gene therapy for locally advanced prostate cancer – where do we stand? , 2000, World Journal of Urology.

[38]  F. Khuri,et al.  Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. , 2000, Cancer research.

[39]  J. Roth,et al.  Contribution of CD95 Ligand-Induced Neutrophil Infiltration to the Bystander Effect in p53 Gene Therapy for Human Cancer1 , 2000, The Journal of Immunology.

[40]  W. Russell,et al.  Update on adenovirus and its vectors. , 2000, The Journal of general virology.

[41]  Suxing Liu,et al.  Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models , 2000, Cancer Gene Therapy.

[42]  M. Widschwendter,et al.  New insights into p53 regulation and gene therapy for cancer. , 2000, Biochemical pharmacology.

[43]  L. Johnson,et al.  An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy , 2000, Nature Medicine.

[44]  B. Hann,et al.  Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015) , 2000, Nature Medicine.

[45]  J. Roth,et al.  Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection. , 2000, Chest.

[46]  R. Herrmann,et al.  P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients , 2000, Cancer Gene Therapy.

[47]  P. Liang,et al.  Identification of a Novel Ligand-Receptor Pair Constitutively Activated by ras Oncogenes* , 2000, The Journal of Biological Chemistry.

[48]  M. Bernstein,et al.  Adenoviral Vector-mediated Gene Transfer: Timing of Wild-type P53 Gene Expression in vivo and Effect of Tumor Transduction on Survival in a Rat Glioma Brachytherapy Model , 2000, Journal of Neuro-Oncology.

[49]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[50]  J. Bergh,et al.  Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors , 2000, Cancer Gene Therapy.

[51]  N D Marchenko,et al.  Death Signal-induced Localization of p53 Protein to Mitochondria , 2000, The Journal of Biological Chemistry.

[52]  F. Lacroix,et al.  Cancer gene therapy mediated by CTS1, a p53 derivative: Advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2 , 2000, Cancer Gene Therapy.

[53]  C. Springer,et al.  Prodrug-activating systems in suicide gene therapy. , 2000, The Journal of clinical investigation.

[54]  T. Caspari.  Checkpoints: How to activate p53 , 2000, Current Biology.

[55]  D. Kirn,et al.  In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. , 2000, Cancer research.

[56]  M. Gulley,et al.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  F. Khuri,et al.  Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[59]  A. Levine,et al.  Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. , 1999, Genes & development.

[60]  G. Clayman,et al.  Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  D. Kirn,et al.  Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. , 1999, Cancer research.

[62]  F. Khuri,et al.  Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. , 1999, Journal of the National Cancer Institute.

[63]  C. Miller,et al.  A system for the propagation of adenoviral vectors with genetically modified receptor specificities , 1999, Nature Biotechnology.

[64]  Y. Nakamura,et al.  Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  B. Wouters,et al.  Apoptosis, p53, and tumor cell sensitivity to anticancer agents. , 1999, Cancer research.

[66]  R. Grand,et al.  The Replicative Capacities of Large E1B-Null Group A and Group C Adenoviruses Are Independent of Host Cell p53 Status , 1999, Journal of Virology.

[67]  F. Goodrum,et al.  p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection , 1998, Journal of Virology.

[68]  A. Hengstermann,et al.  Replication of ONYX-015, a Potential Anticancer Adenovirus, Is Independent of p53 Status in Tumor Cells , 1998, Journal of Virology.

[69]  Z. Su,et al.  The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[70]  T. Liu,et al.  Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  R. Herrmann,et al.  A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. , 1998, Human gene therapy.

[72]  W. Hong,et al.  Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. , 1998, Seminars in oncology.

[73]  J. Coll,et al.  Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy , 1998, Gene Therapy.

[74]  S. Lippman,et al.  Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  Michael Weller,et al.  Predicting response to cancer chemotherapy: the role of p53 , 1998, Cell and Tissue Research.

[76]  L. Nielsen,et al.  Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[77]  E. Canning,et al.  A triploblast origin for Myxozoa? , 1998, Nature.

[78]  K. Hunt,et al.  P53 Carcinoma Cell Lines and Does Not Require Factor E2f-1 Induces Apoptosis in Human Breast and Ovarian Adenovirus-mediated Overexpression of the Transcription Updated Version Citing Articles E-mail Alerts Adenovirus-mediated Overexpression of the Transcription Factor E2f-1 Induces Apoptosis in Hum , 2013 .

[79]  D. Fisher,et al.  Apoptosis in tumorigenesis and cancer therapy. , 1997, Frontiers in bioscience : a journal and virtual library.

[80]  D. Kirn,et al.  ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents , 1997, Nature Medicine.

[81]  E. Maxwell,et al.  Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. , 1997, Cancer gene therapy.

[82]  J. Bergelson,et al.  Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5 , 1997, Science.

[83]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[84]  W. McBride,et al.  Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. , 1996, Cancer research.

[85]  J. Roth,et al.  Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. , 1996, The Journal of thoracic and cardiovascular surgery.

[86]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[87]  X. Chen,et al.  p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. , 1996, Genes & development.

[88]  M. Westphal,et al.  Adenovirus‐mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo , 1996, International journal of cancer.

[89]  W. Hong,et al.  Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.

[90]  Z. Su,et al.  The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[91]  C. Prives,et al.  p53: puzzle and paradigm. , 1996, Genes & development.

[92]  W. Yung,et al.  Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. , 1996, Cancer research.

[93]  J. Bruner,et al.  Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. , 1996, Oncogene.

[94]  Z. Su,et al.  Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. , 1995, Oncogene.

[95]  Jianxiang,et al.  In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. , 1995, Cancer research.

[96]  B. Badie,et al.  Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. , 1995, Neurological research.

[97]  H. Ertl,et al.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.

[98]  J. Roth,et al.  Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. , 1994, Journal of the National Cancer Institute.

[99]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[100]  J. Roth,et al.  Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. , 1994, Cancer research.

[101]  A. Levine,et al.  Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. , 1994, Cancer research.

[102]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[103]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[104]  J. Roth,et al.  A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. , 1993, Cancer research.

[105]  K. Ligon,et al.  Detection ofp53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reaction , 1993, Journal of Neuro-Oncology.

[106]  S. Korsmeyer,et al.  The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[107]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[108]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[109]  Yumay Chen,et al.  Genetic mechanisms of tumor suppression by the human p53 gene , 1990, Science.

[110]  A. Berk,et al.  Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. , 1990, Virology.

[111]  J. Darnell,et al.  Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport , 1985, Molecular and cellular biology.

[112]  C. Densmore,et al.  Aerosol delivery of PEI–p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis , 2002, Cancer Gene Therapy.

[113]  C. Kemp,et al.  p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. , 2001, Cancer research.

[114]  R. Perez-soler,et al.  EGF receptor and p21WAF1 expression are reciprocally altered as ME-180 cervical carcinoma cells progress from high to low cisplatin sensitivity. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[115]  S. H. van der Burg,et al.  Strategies for immunotherapy of cancer. , 2000, Advances in immunology.

[116]  Z. Su,et al.  Mda-7, a novel melanoma differentiation associated gene with promise for cancer gene therapy. , 2000, Advances in experimental medicine and biology.

[117]  Y. Nakamura,et al.  The role of p53-target genes in human cancer. , 2000, Critical reviews in oncology/hematology.

[118]  L Ji,et al.  A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax , 2000, Gene Therapy.

[119]  F. Khuri,et al.  Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53) , 2000, Cancer Gene Therapy.

[120]  H. Kauczor,et al.  CT-guided intratumoral gene therapy in non-small-cell lung cancer , 1999, European Radiology.

[121]  L. Nielsen,et al.  Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer , 1999, Cancer Chemotherapy and Pharmacology.

[122]  L. Milas,et al.  Apoptosis in tumor biology and therapy. , 1997, Advances in experimental medicine and biology.

[123]  A. Berk,et al.  Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. , 1987, Virology.